ANTIVIRAL THERAPY FOR HUMAN PAPILLOMAVIRUSES - RATIONALE AND PROSPECTS

被引:47
作者
PHELPS, WC [1 ]
ALEXANDER, KA [1 ]
机构
[1] DUKE UNIV, MED CTR, DURHAM, NC USA
关键词
D O I
10.7326/0003-4819-123-5-199509010-00008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To review the basic virology of human papillomavirus (HPV) and the natural history of HPV infection and to discuss current and potential therapies. Data Sources: The MEDLINE database (1966 to 1994) was searched to identify English-language articles and abstracts on HPV biology and antiviral chemotherapy. Study Selection: Peer-reviewed basic science and clinical research studies on the molecular, cellular, and human biology of HPV infection. Data Extraction: Summaries of data from research studies on the biology of papillomavirus infection and information from review articles on the basic and applied pharmacology of antiviral agents. Data Synthesis: Papillomavirus infections are very common. Human papillomavirus infections may be asymptomatic or may be manifested in various benign or malignant lesions, most notably anogenital condyloma and anogenital carcinoma. Currently, therapeutic options for HPV infection are limited, expensive, and often ineffective. By understanding the basic virology and natural history of HPV infection, potential sites for pharmacologic intervention can be identified. Although currently available antiviral compounds are inactive against HPV, they serve as models for the rational design of HPV antiviral drugs. Conclusions: Although HPV infection causes substantial morbidity and expense, uniformly effective therapy for HPV infection is not currently available. Several processes in the HPV infection cycle are appropriate targets for the development of antiviral agents. The development of compounds active against HPV could prevent the benign and malignant diseases associated with HPV infection.
引用
收藏
页码:368 / 382
页数:15
相关论文
共 229 条
  • [31] TRANSFORMING ACTIVITY OF E5A PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE-6 IN NIH-3T3 AND C127 CELLS
    CHEN, SL
    MOUNTS, P
    [J]. JOURNAL OF VIROLOGY, 1990, 64 (07) : 3226 - 3233
  • [32] COHEN KA, 1991, J BIOL CHEM, V266, P14670
  • [33] LOSS OF MHC CLASS-I EXPRESSION IN CERVICAL CARCINOMAS
    CONNOR, ME
    STERN, PL
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (06) : 1029 - 1034
  • [34] LARYNGEAL PAPILLOMA - ETIOLOGIC AND THERAPEUTIC CONSIDERATIONS
    COOK, TA
    BRUNSCHW.JP
    BUTEL, JS
    COHN, AM
    GOEPFERT, H
    RAWLS, WE
    [J]. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1973, 82 (05) : 649 - 655
  • [35] ANTIGEN PRESENTATION AND T-CELL ACTIVATION IN EPIDERMODYSPLASIA VERRUCIFORMIS
    COOPER, KD
    ANDROPHY, EJ
    LOWY, D
    KATZ, SI
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1990, 94 (06) : 769 - 776
  • [36] ANTIVIRAL PROPERTIES OF RO 31-8959, AN INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PROTEINASE
    CRAIG, JC
    DUNCAN, IB
    HOCKLEY, D
    GRIEF, C
    ROBERTS, NA
    MILLS, JS
    [J]. ANTIVIRAL RESEARCH, 1991, 16 (04) : 295 - 305
  • [37] CONTINUED EXPRESSION OF HPV-16 E7 PROTEIN IS REQUIRED FOR MAINTENANCE OF THE TRANSFORMED PHENOTYPE OF CELLS CO-TRANSFORMED BY HPV-16 PLUS EJ-RAS
    CROOK, T
    MORGENSTERN, JP
    CRAWFORD, L
    BANKS, L
    [J]. EMBO JOURNAL, 1989, 8 (02) : 513 - 519
  • [38] DEGRADATION OF P53 CAN BE TARGETED BY HPV E6 SEQUENCES DISTINCT FROM THOSE REQUIRED FOR P53 BINDING AND TRANSACTIVATION
    CROOK, T
    TIDY, JA
    VOUSDEN, KH
    [J]. CELL, 1991, 67 (03) : 547 - 556
  • [39] Crumpacker C. S., 1984, CLIN APPLICATIONS RI, P33
  • [40] THE NUCLEOTIDE-SEQUENCE AND GENOME ORGANIZATION OF HUMAN PAPILLOMA-VIRUS TYPE-11
    DARMANN, K
    SCHWARZ, E
    GISSMANN, L
    HAUSEN, HZ
    [J]. VIROLOGY, 1986, 151 (01) : 124 - 130